BioMedWire

Expert Highlights Growing Evidence That Links Respiratory Infections to Cardiovascular Diseases

IBN.ai — Tue, 14 Jul 2026 14:05:00 +0000

Not many people know that respiratory infections have been strongly linked to cardiovascular disease events, and this knowledge gap is leading to missed opportunities to use readily accessible vaccines to limit the severity and challenges arising from cardiovascular disease. Professor Colin Russell, based at the School of Medicine at Amsterdam University, explains why it is important to understand the role that respiratory infections play in cardiovascular disease.

Another important aspect to emphasize besides respiratory infection vaccination is timely diagnosis and treatment so that the infection isn’t given an opportunity to progress to a level that is severe or puts lives at risk. This is why companies like Co-Diagnostics Inc. (NASDAQ: CODX) focused on developing…

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D

IBN.ai — Tue, 14 Jul 2026 13:50:00 +0000

Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology.
VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform.
The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design.
AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns.
The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.

Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).

The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for…

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Ethics Approval for Phase II Ebola Trial in DRC

IBN.ai — Mon, 13 Jul 2026 15:43:54 +0000

NanoViricides, Inc. (NYSE American: NNVC) announced it has received National Ethics Committee approval in the Democratic Republic of the Congo (“DRC”) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and noted that NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation if regulatory approval is received.

NanoViricides said NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings. The company believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines.

To view the full press release, visit https://ibn.fm/MuxOe

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives

IBN.ai — Mon, 13 Jul 2026 14:20:00 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA(R) (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.

Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.

To view the full press release, visit https://ibn.fm/tVAj3

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Completes Analytical Reference Standard Program for ONC010

IBN.ai — Mon, 13 Jul 2026 13:15:00 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. Completed in collaboration with Dalton Pharma Services, the program established a qualified reference standard to support analytical testing, manufacturing consistency, quality control and future regulatory and clinical activities.

The milestone strengthens the company’s chemistry, manufacturing and controls (“CMC”) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development and chiral purity testing. Onco-Innovations said the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization and quality control systems.

To view the full press release, visit https://ibn.fm/EefIN

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

IBN.ai — Fri, 10 Jul 2026 14:05:00 +0000

Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors.

For patients with this cancer, there is reason to hope because existing treatment approaches, such as surgery and radiotherapy haven’t proved to be very successful in halting disease recurrence. As the team painstakingly takes their innovation through the clinical development process, other efforts by for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also moving along at an encouraging…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Why Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

IBN.ai — Thu, 09 Jul 2026 18:25:46 +0000

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need. The publication reads, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.”

To view the full article, visit https://ibn.fm/JtLc5

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

IBN.ai — Wed, 08 Jul 2026 13:50:00 +0000

Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development
This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource
ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate
This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline

Earth Science Tech (OTC: ETST) has shown how its fundamental competitive advantages is able to build profit while serving its expanding base of customers more effectively. As a multifaceted and diversified holding company, ETST creates value by acquiring, operating, optimizing, and managing autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development. This strategy is baked in to the company’s “conglomerate” business model, which deviates from the traditional healthcare stock, insulating the company from sector-specific risks and shocks.

Within the healthcare domain, ETST is focused on building a vertically integrated platform that seamlessly integrates all aspects of patient care, from telemedicine (consultation) and pharmacy, through to fulfillment. With Peak Curative LLC, the company’s wholly owned subsidiary and…

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at  https://ibn.fm/ETST

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Launches AI-Powered ZetaOmics Computational Biology Platform

IBN.ai — Wed, 08 Jul 2026 13:21:53 +0000

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai, introducing an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.

According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.

To view the full press release, visit https://ibn.fm/9sIIl

About Lantern Pharma Inc..

Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai , Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Positive Safety Review for Phase 1b Sapu003 Trial

IBN.ai — Tue, 07 Jul 2026 14:45:58 +0000

Oncotelic Therapeutics (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003, finding no dose-limiting toxicities and recommending advancement to the next planned dose level. The company also announced plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment.

Oncotelic said the clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle(TM) nanomedicine platform and the intravenous everolimus formulation Sapu003. The company said the publication supports the platform’s scalable manufacturing capabilities, stability and preclinical antitumor activity while reinforcing the ongoing clinical development program.

To view the full press release, visit https://ibn.fm/sBbID

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic’s relationship with SAPU Bio — an OEB-5 sterile injectable cGMP manufacturing facility — PDAOAI underpins the Platform and its ongoing joint development work with TechForce Robotics, Oncotelic’s strategic robotics and automation partner.

For more information, please visit www.oncotelic.com

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Activates All Australian Phase IIa Trial Sites for ONP-002

IBN.ai — Tue, 07 Jul 2026 14:18:18 +0000

Oragenics (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants following the activation of Royal Adelaide Hospital. The company said no serious adverse events have been reported in dosed participants to date and it continues to target a Phase IIa data readout in the fourth quarter of 2026. Oragenics also announced it submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company said the meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026.

To view the full press release, visit https://ibn.fm/Yye2E

About Oragenics, Inc.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The Company is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002 , with U.S. Phase 2b trials planned to follow. The Company’s intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Supreme Court Ruling Could Worsen the US Healthcare Crisis

IBN.ai — Tue, 07 Jul 2026 14:05:00 +0000

There is general agreement that the healthcare system in the U.S. is in crisis, and a recent ruling issued by the Supreme Court could worsen the situation. This particular ruling allowed the federal government to end the TPS (temporary protected status) of noncitizens from particular countries, in this case Syria and Haiti.

Stakeholders like Astiva Health are likely to be monitoring this situation closely since California is estimated to have about 60,000 TPS holders from different countries, including…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

IBN.ai — Tue, 07 Jul 2026 13:50:00 +0000

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration.
Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions.

What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis (“OA”).

Today, advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Among them is Regentis Biomaterials Ltd. (NYSE American: RGNT) Gelrin C, a cell-free, 10-minute procedure of an off-the-shelf hydrogel designed to support…

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai.

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN.

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Study Highlights Prognostic Value of Nu.Q Cancer Assay in Lung Cancer

IBN.ai — Tue, 07 Jul 2026 13:29:48 +0000

VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted with researchers and clinicians at France’s Hospices Civils de Lyon, the real-world study found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival, while a prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review.

Volition said the findings support the potential use of Nu.Q Cancer to help personalize treatment selection and improve clinical decision-making. The company added that clinical certification of the test at Hospices Civils de Lyon has been completed and that it is preparing a reimbursement submission in France under the RIHN framework. Volition also said it is pursuing commercialization opportunities with hospital networks and potential licensing partners internationally, with reimbursement representing a key milestone toward routine clinical use in France.

To view the full press release, visit https://ibn.fm/dhJZ6

About Volition 

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

For further information, visit the company’s website at https://volition.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

UCS Unveils Tool to Track Attacks Against Science in the US

IBN.ai — Mon, 06 Jul 2026 14:05:00 +0000

The Union of Concerned Scientists (UCS) has unveiled an interactive tool geared toward documenting and highlighting the different ways through which science has come under attack from the time Trump took office for the second time. The tool also documents possible violations of draft legislation before Congress, called the Scientific Integrity Act.

For companies like Co-Diagnostics Inc. (NASDAQ: CODX) focused on working as best they can to develop tools that improve infectious disease diagnosis, attacks…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

IBN.ai — Mon, 06 Jul 2026 13:25:00 +0000

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.

To view the full press release, visit https://ibn.fm/xT F 5q

About VERAXA Biotech AG (NASDAQ: VRXA)

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy

IBN.ai — Thu, 02 Jul 2026 14:05:00 +0000

Scientists have for long been concerned about why some people with liver cancer respond when given immunotherapy but others don’t. A recent comprehensive review provides key insights linking how patients respond to these treatments to the status of their gut microbiome.

As more is understood about the different ways in which the gut microbiome can be supported to make checkpoint-inhibitors or blockades more effective, the treatments being developed by several firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) could be supercharged to…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

IBN.ai — Thu, 02 Jul 2026 13:19:20 +0000

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.

VERAXA said its BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.

To view the full press release, visit https://ibn.fm/FCIlk

About VERAXA Biotech AG (NASDAQ: VRXA)

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Promotes Cheng Fang to Chief Scientific Officer

IBN.ai — Wed, 01 Jul 2026 13:35:22 +0000

Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.

The company said Fang’s promotion comes as it advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. Annovis said Fang has played a key role in advancing the company’s clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones.

To view the full press release, visit https://ibn.fm/c9jdt

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.

For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

IBN.ai — Tue, 30 Jun 2026 18:54:42 +0000

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management.

“The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from tools that help identify elevated risk or silent disease before they progress,” reads a recent article. “This preventive focus aligns with broader trends in healthcare, where organizations are increasingly emphasizing population health management and proactive risk reduction.”

To view the full article, visit https://ibn.fm/6swfk

About Cardio Diagnostics Holdings Inc.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

HeartBeam Inc. (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

IBN.ai — Tue, 30 Jun 2026 14:35:00 +0000

Advances in digital health, cloud computing and data analytics are making it possible to move beyond episodic monitoring toward a more comprehensive understanding of cardiovascular health.
HeartBeam’s proprietary HeartBeam System reflects the company’s mission to make cardiac monitoring accessible beyond the walls of a medical facility.
The synthesized 12-lead ECG view provided by the system can help clinicians evaluate rhythm abnormalities and identify rhythm changes that may warrant additional investigation.

Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of a healthcare facility. As healthcare increasingly emphasizes earlier intervention and more personalized care, HeartBeam (NASDAQ: BEAT) is developing technologies designed to transform where and how cardiac data are captured, analyzed and shared, including its proprietary, FDA-cleared HeartBeam System, the first portable, cable-free ECG system capable of synthesizing a 12-lead ECG for assessment of arrhythmias.

For decades, cardiac monitoring has relied on the standard 12-lead ECG but its use has been confined to clinical settings, requiring bulky equipment, adhesive electrodes and trained personnel to administer. This means the most clinically meaningful cardiac data is only available in a doctor’s office or hospital and…

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer

IBN.ai — Tue, 30 Jun 2026 14:05:00 +0000

Researchers at University of Washington have discovered that a drug that is currently approved by the FDA could help in boosting the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors.

While this study focused on fibrolamellar carcinoma, other types of cancer are also getting unprecedented levels of research attention from companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI). Checkpoint inhibition therapy against cancer is…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Manufacturing and Development Efforts as It Pursues a Novel Approach to Hard-to-Treat Cancers

IBN.ai — Tue, 30 Jun 2026 13:05:00 +0000

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

Onco-Innovations is advancing a new class of DNA Damage Response (“DDR”) therapies through the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors designed to disrupt cancer cells’ ability to repair DNA damage.
The company recently achieved a key manufacturing milestone with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010.
A newly signed Letter of Intent with Nanosoft Polymers is expected to support polymer development, drug delivery optimization and formulation work for the ONC010 program.

Cancers frequently exhibit defective repair of damaged DNA, leading to the accumulation of mutations that can give rise to unchecked growth, evasion of the immune system, and the capacity to spread. Conventional DNA damaging therapies, like radiation treatment or some chemotherapies, can overwhelm a cancer’s limited repair capacity resulting in cancer cell death. However, some cancers retain sufficient DNA repair capacity to resist these treatments at doses patients can tolerate.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within this rapidly evolving area of oncology through the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors. PNKP plays a critical role in repairing damaged DNA, and the company’s…

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform

IBN.ai — Mon, 29 Jun 2026 14:23:15 +0000

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle(TM) nanoparticle platform through the development of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial. The publication details the platform’s formulation design, scalable cGMP manufacturing process, product stability and preclinical performance, while demonstrating its potential to enable intravenous delivery of poorly water-soluble therapeutic compounds.

The company said the research also supports broader applications for the Deciparticle(TM) platform beyond everolimus, including additional hydrophobic drug candidates. Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors to assess its safety, pharmacokinetics and preliminary antitumor activity in combination with exemestane.

To view the full press release, visit https://ibn.fm/gECtl

About Oncotelic Therapeutics

For more information, please visit www.oncotelic.com

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

IBN.ai — Fri, 26 Jun 2026 16:05:00 +0000

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops.
What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level.

Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full…

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification

IBN.ai — Fri, 26 Jun 2026 14:47:49 +0000

BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with anti-doping standards established by the World Anti-Doping Agency and the UFC. Combined with the previously certified MyndMed(TM) daytime formula, the company said MyndSystem(TM) is now a fully WADA-compliant 24/7 cognitive performance and recovery system for professional athletes.

The company said the certification strengthens its position in the sports nutrition market by supporting potential adoption among professional athletes while also targeting executives and active seniors. BioAdaptives said the milestone could enhance commercialization opportunities, strategic partnerships and broader market adoption as it expands the MyndSystem(TM) platform.

To view the full press release, visit https://ibn.fm/JNHRs

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

For more information, please visit our website at www.bioadaptives.com.

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

US Health Care Expenditure Spiked to Nearly $6 Trillion in 2025

IBN.ai — Fri, 26 Jun 2026 14:05:00 +0000

According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7tn in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity.

Escalating health care costs are also bound to be of major concern to Astiva Health and other providers of health insurance policies as…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Researchers Urge Caution in Using Antibiotic Prophylaxis

IBN.ai — Thu, 25 Jun 2026 14:05:00 +0000

The medical community has for long relied on antibiotic prophylaxis, the practice of prescribing antibiotics to safeguard at-risk individuals from bacterial infections. However, a new publication has sounded the alarm on the widespread use of these “just in case” treatments due to their risk of driving antibiotic resistance.

The dilemma that clinicians face is that it is often difficult to detect these infections before they have progressed to a level where they can quickly spread from one individual to another. Perhaps entities like Co-Diagnostics Inc. (NASDAQ: CODX) could be of help in…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment

IBN.ai — Thu, 25 Jun 2026 13:46:48 +0000

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis (“MS”), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled “The Quest to Repair What Multiple Sclerosis Takes Away,” highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely.

The editorial discusses Quantum BioPharma’s development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance into Phase 2 clinical trials as it pursues a novel approach to treating the disease.

To view the full press release, visit https://ibn.fm/WikKX

About Quantum BioPharma Ltd.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies

IBN.ai — Wed, 24 Jun 2026 13:48:51 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development across multiple cancer indications.

The editorial noted that ONC010(TM) has demonstrated encouraging preclinical results, including extended survival and tumor growth reduction in colorectal cancer models, while the company advances manufacturing, formulation and IND-enabling activities through partnerships with Dalton Pharma Services and Nucro-Technics. Onco-Innovations also acquired Inka Health Corp., whose SynoGraph(TM) causal AI platform is designed to support patient stratification and clinical trial design as the company prepares for anticipated first-in-human studies. The report highlighted continued innovation across the biotechnology sector, citing recent regulatory and clinical milestones reported by Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), GSK plc (NYSE: GSK) and Gilead Sciences Inc. (NASDAQ: GILD).

To view the full press release, visit https://ibn.fm/cFCop

About Onco-Innovations Limited

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial

IBN.ai — Wed, 24 Jun 2026 13:09:39 +0000

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that enrollment in its Phase 3 APPROACH clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86% and remains on track. The study is one of the company’s Phase 3 trials supporting development of HLP003, its lead proprietary novel serotonergic agonist, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

The APPROACH study is part of Helus Pharma’s broader Phase 3 PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. The company said the enrollment milestone supports its goal of reporting topline data from APPROACH in the fourth quarter of 2026 as it advances HLP003 toward potential commercialization for patients with major depressive disorder.

To view the full press release, visit https://ibn.fm/Qpikw

About Helus Pharma

Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019 (the “Company”), is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.

NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

IBN.ai — Tue, 23 Jun 2026 14:35:00 +0000

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs.
By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs.
Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment.

The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.

One company pursuing this strategy is Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on developing novel oncology solutions. The company’s proprietary Deciparticle(TM) platform utilizes nanoparticle engineering to reformulate hydrophobic drugs into…

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment

IBN.ai — Tue, 23 Jun 2026 14:05:00 +0000

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma. The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat.

For now, there is hope that this injectable vaccine can change the trajectory of patients’ lives after receiving a glioblastoma diagnosis. With other companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) also developing new formulations…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies

IBN.ai — Tue, 23 Jun 2026 13:49:52 +0000

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced its inclusion in a BioMedWire editorial examining the growing market for DNA Damage Response inhibitor (“DDRi”) therapies and the next generation of cancer treatments targeting DNA repair pathways. The article highlights the company’s lead candidate, ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a key DNA repair enzyme involved in multiple repair mechanisms, positioning Onco-Innovations among emerging developers seeking to advance new synthetic lethality approaches in precision oncology.

To view the full press release, visit https://ibn.fm/3dhdy

About Onco-Innovations Limited

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program

IBN.ai — Tue, 23 Jun 2026 13:26:50 +0000

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced its inclusion in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (“MS”), a disease affecting more than 2.9 million people worldwide. The article highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS, and notes that the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease.

To view the full press release, visit https://ibn.fm/KdvrI

About Quantum BioPharma Ltd.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial

IBN.ai — Mon, 22 Jun 2026 14:28:29 +0000

NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.

NanoViricides said the trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. The company also noted that NV-387, a broad-spectrum antiviral candidate, has been proposed for evaluation against Ebola virus infections and that the shipment makes the drug locally available should it be utilized in response efforts. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.

To view the full press release, visit https://ibn.fm/CTIZc

About NanoViricides

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies

IBN.ai — Mon, 22 Jun 2026 14:13:01 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) was featured in a BioMedWire editorial examining the rapidly expanding DNA Damage Response inhibitor market, where new drug classes are emerging beyond PARP inhibitors. The company is advancing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to the editorial, Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is positioning itself as an early leader in a novel class of cancer therapeutics.

Onco-Innovations highlighted preclinical data showing ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile. The editorial also noted the company’s progress in manufacturing scale-up, IND-enabling studies and planned first-in-human clinical development, supported by its proprietary SynoGraph(TM) causal AI platform through subsidiary Inka Health. The feature additionally reviewed recent developments across the oncology and biotechnology sectors involving AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX).

To view the full press release, visit https://ibn.fm/HH1VP

About Onco-Innovations Limited

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Why Men Need Sexual Health Help While Undergoing Cancer Treatment

IBN.ai — Mon, 22 Jun 2026 14:05:00 +0000

About 90% of men that undergo prostate cancer treatment, and almost 50% of men treated for different kinds of cancer suffer a degree of sexual dysfunction or erectile challenges. Most hardly ever open up about these issues and they suffer in silence. This needn’t be so, because there are many ways through which sexual challenges can be addressed for men with cancer.

As the quest for better cancer treatments that have minimal side effects progresses at companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), there is hope that…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances ONC010 Program With Successful 300-Gram API Scale-Up Batch

IBN.ai — Mon, 22 Jun 2026 13:10:00 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient supporting its proprietary ONC010 drug candidate. The batch, produced as part of Dalton Pharma Services’ Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents following comprehensive quality control and Certificate of Analysis review, marking an important manufacturing milestone for the company’s PNKP inhibitor program.

Onco-Innovations said the scale-up campaign demonstrates the reproducibility and scalability of the manufacturing process and is expected to support future analytical qualification, formulation development, engineering batch production and GMP manufacturing activities ahead of planned First-in-Human studies. The company also announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately, succeeding Nico Mah.

To view the full press release, visit https://ibn.fm/NJVb1

About Onco-Innovations Limited

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention

IBN.ai — Mon, 22 Jun 2026 13:08:19 +0000

VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC(TM)-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.

VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.

To view the full press release, visit https://ibn.fm/1je4A

About VERAXA Biotech AG (NASDAQ: VRXA)

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Positions AI Voice Analysis as Scalable Testing Alternative

IBN.ai — Thu, 18 Jun 2026 17:05:11 +0000

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) was featured in a recent TechMediaWire Podcast, where CEO Justin Hanka discussed the company’s plans to commercialize AI-powered voice analysis technology designed to detect alcohol and drug intoxication through non-invasive speech assessment. During the interview, Hanka explained that the company has built prediction models using more than 50 million data points collected through years of clinical research, enabling the identification of intoxication indicators associated with alcohol and drug use. MindBio believes its technology offers a scalable alternative to traditional testing methods that require biological samples, with potential applications in mining, aviation, construction, law enforcement and other safety-sensitive industries. The company is developing enterprise deployment systems that combine proprietary software with Edge-AI kiosks capable of delivering assessments in less than three seconds and expects to begin live workplace testing during the second quarter of 2026. Looking beyond workplace impairment detection, management also sees broader opportunities for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions.

To view the full article, visit https://ibn.fm/HJarm

About MindBio Therapeutics Corp.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports Fiscal 2026 Revenue Growth, Higher Earnings

IBN.ai — Thu, 18 Jun 2026 14:15:00 +0000

Earth Science Tech (OTC: ETST) reported financial results for the fiscal year ended March 31, 2026, highlighted by revenue of $35.7 million, up 8% from the prior year, gross profit of $25.5 million, up 5%, and net income of $3.6 million, an 11% increase compared with fiscal 2025. Total assets rose 27% year over year to $9.0 million as the company continued expanding its integrated healthcare platform across telemedicine, pharmacy and fulfillment services.

The company also emphasized its capital allocation strategy, noting it repurchased and retired more than 4 million shares during fiscal 2026 and more than 7.1 million shares through fiscal 2026 and subsequent periods. Management said the company generated positive operating cash flow, strengthened its balance sheet without adding debt and remains focused on growth initiatives, product expansion and continued share repurchases as it enters fiscal 2027.

To view the full press release, visit https://ibn.fm/NpjTw

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

The core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

CMS Issues Final Rules on Medicaid Eligibility Work Requirements

IBN.ai — Thu, 18 Jun 2026 14:05:00 +0000

Last year, Congress passed changes to Medicaid eligibility requirements and CMS was given a deadline to issue final rules on those work requirements. The federal agency has since published those final rules and enrollees on the Medicaid program need to acquaint themselves with these requirements to ensure they comply in order to retain their eligibility. We discuss some of those requirements.

Health care system stakeholders like Astiva Health will be monitoring how these…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform

IBN.ai — Thu, 18 Jun 2026 13:23:13 +0000

VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC(TM)-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.

VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.

To view the full press release, visit https://ibn.fm/QiPhH

About VERAXA Biotech AG (NASDAQ: VRXA)

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Collaborates with Sysmex to Advance Nu.Q® NETs Assay Development

IBN.ai — Wed, 17 Jun 2026 13:46:24 +0000

VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.

Volition said the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8 billion.

To view the full press release, visit https://ibn.fm/TSMG4

About Volition

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

For further information, visit the company’s website at https://volition.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Completes AI and Quantum Computing Pilot for PNKP Inhibitor Program

IBN.ai — Wed, 17 Jun 2026 13:11:07 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company’s PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. Kuano delivered molecular modeling and computational findings that strengthened Onco’s understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation.

The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping and AI-assisted generative compound design, with the goal of improving compound prioritization and accelerating progress toward preclinical development.

To view the full press release, visit https://ibn.fm/SdQqD

About Onco-Innovations Limited

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

How Authorities are Protecting Public Health During the FIFA World Cup

IBN.ai — Tue, 16 Jun 2026 14:05:00 +0000

The FIFA World Cup started on June 11 and will end on July 19. 48 national teams are taking part, and this is an extra 16 teams when compared to the number of national teams that participated in the last edition that took place in Qatar in 2022. 100 matches are scheduled to be played across the U.S., Mexico and Canada.

Firms like Co-Diagnostics Inc. (NASDAQ: CODX) are likely to take a keen interest in how infectious disease prevention and control is handled at the local, county, state and federal levels since this is an area where…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model

IBN.ai — Mon, 15 Jun 2026 14:20:19 +0000

Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. According to the study, treatment produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.

The company said the findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. Management noted that the biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer, and said the results complement the company’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer.

To view the full press release, visit https://ibn.fm/BoK2F

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Study Links TBI to Higher Mortality Risk Due to Brain Cancer

IBN.ai — Fri, 12 Jun 2026 14:05:00 +0000

A study conducted by a team at Mass General Brigham has found that people with a history of traumatic brain injury had a higher chance of dying as a result of brain cancer. The findings create an urgency to rethink how TBI cases are handled not just in the immediate aftermath but also over the long term.

As more studies are conducted to uncover the complex relationships between variables like TBI and brain malignancies, it is becoming clearer to drug development firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that it may be necessary to…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Earth Science Tech Inc. (ETST) Reports Transformational Fiscal Year as Share Repurchases and Healthcare Expansion Shape Growth Strategy

IBN.ai — Fri, 12 Jun 2026 13:50:00 +0000

Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation.
Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value.
Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive.
Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting growth within the company’s health and wellness segment.
Management emphasized that expansion initiatives were completed without adding debt to the balance sheet, maintaining a disciplined capital structure.
Investors will have an opportunity to hear directly from management when CEO Giorgio R. Saumat presents at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17.

Earth Science Tech (OTC: ETST), a strategic healthcare-oriented holding company, has spent the past several years reshaping itself from a wellness-focused enterprise into a diversified holding company centered on healthcare, pharmaceutical compounding, telemedicine, real estate, and cash-flow-generating operating businesses. That transformation was a central theme of the company’s annual shareholder letter for the fiscal year ended March 31, 2026, where management highlighted operational progress, balance-sheet discipline, and an ongoing share repurchase strategy that has become a defining element of ETST’s capital allocation approach (https://ibn.fm/WX3CI).

In the letter, CEO and Chairman Giorgio R. Saumat described fiscal 2026 as a year in which the company strengthened the foundation for future growth while maintaining a debt-free approach to…

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq

IBN.ai — Thu, 11 Jun 2026 14:45:00 +0000

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.

VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.

To view the full press release, visit https://ibn.fm/ka00j

About VERAXA Biotech AG (NASDAQ:VRXA)

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology.

For regular updates about VERAXA Biotech, visit www.veraxa.com

About Voyager Acquisition Corp.

Voyager is a special purpose acquisition company with a bold mission: to revolutionize the healthcare sector through a merger, stock purchase, or business combination. Our team of experienced executives includes unparalleled expertise in investing, operations, and medical innovation, supported by a vast network of connections. With these strengths, we not only seek to drive success but commit to scaling companies to unprecedented heights in the healthcare industry.

For more information, please visit https://www.voyageracq.com

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness

IBN.ai — Thu, 11 Jun 2026 14:05:00 +0000

CAR-T therapy has been transformational in treating many blood cancers, such as leukemia and lymphoma. However, this treatment approach hasn’t worked for solid tumors, and it also reaches a point and becomes ineffective in blood cancers. A new study just found a way to boost the lifespan and efficacy window of these important immune cells that help fight cancer.

This preclinical breakthrough comes at a time when numerous academic institutions and for-profit entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also making their own…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Hospitals Take the Lead in Tackling Health Care Access and Affordability

IBN.ai — Tue, 09 Jun 2026 14:05:00 +0000

Hospitals have come under the spotlight as public concern about the health care cost crisis reaches unprecedented levels. The president of the American Hospital Association (AHA) wrote an article last week outlining how hospitals are taking steps to ensure that access and affordability issues are addressed so that Americans can continue to enjoy the high quality of care that they have come to expect from the health care system.

It would be interesting to hear what Medical Advantage policy providers like Astiva Health have to say about the urgent measures that need to be…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

IBN.ai — Mon, 08 Jun 2026 14:08:41 +0000

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.

The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.

To view the full press release, visit https://ibn.fm/QOWWK

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program

IBN.ai — Mon, 08 Jun 2026 13:53:24 +0000

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company expects development of finished ibogaine drug products to begin this summer at its GMP-certified manufacturing facility in British Columbia, with plans to produce standardized 50 mg and 100 mg encapsulated dosage formats for research and regulated access programs.

The update comes amid growing interest in ibogaine research and expanding public funding for psychedelic therapies, including a recently announced $50 million program in Texas. Optimi said its development program will include formulation, manufacturing validation, analytical testing and packaging processes, leveraging the same GMP infrastructure currently used to produce psilocybin and MDMA products. Management believes Canada’s regulatory framework and the company’s existing licenses position Optimi to support increasing demand for GMP-grade ibogaine for clinical research and potential therapeutic applications.

To view the full press release, visit https://ibn.fm/IAz1L

About Optimi Health Corp.

Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.

Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit www.optimihealth.ca or optimi.net.

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

IBN.ai — Mon, 08 Jun 2026 13:50:00 +0000

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.

Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.

Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body.

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can…

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance

IBN.ai — Mon, 08 Jun 2026 13:36:27 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate.

The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees. Onco said his background in capital markets and corporate finance is expected to support the company’s oncology-focused growth strategy and ongoing engagement with investors and other stakeholders.

To view the full press release, visit https://ibn.fm/JB4rY

About Onco-Innovations Limited

For more information go to https://oncoinnovations.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Showcase AI Drug Discovery Platform at Qdrant Vector Space Day 2026

IBN.ai — Mon, 08 Jun 2026 13:25:00 +0000

Oncotelic Therapeutics (OTCQB: OTLC) announced that its proprietary PDAOAI(TM) drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.

The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.

To view the full press release, visit https://ibn.fm/Ce72F

About Oncotelic Therapeutics, Inc.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The Company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The Company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

LA Calls for Infectious Diseases Vigilance During World Cup

IBN.ai — Fri, 05 Jun 2026 14:05:00 +0000

This month and in July, the SoFi Stadium in Los Angeles County will host several World Cup matches, and other tournament-related activities will take place within the county. Accordingly, the health department of the county has put health care providers on notice to be alert for infectious diseases during the tournament.

It is unclear whether this capacity exists, but firms like Co-Diagnostics Inc. (NASDAQ: CODX) are massively investing in developing PCR test kits that can be used at…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Launches Intox AI(TM) for Validation and Testing

IBN.ai — Thu, 04 Jun 2026 17:00:00 +0000

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the launch of its Intox AI(TM) software platform for validation and testing. The AI-driven voice analytics solution is designed to detect intoxication and fatigue by analyzing speech patterns and is capable of identifying indicators associated with cocaine, cannabis, alcohol, psychedelics, narcotics and human fatigue. The company said the technology is intended for deployment through Edge AI kiosks currently nearing prototype manufacturing completion.

MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6) (OTCQB: MBQIF) is targeting commercialization opportunities in industries where drug, alcohol and fatigue testing are critical to workplace safety, including mining, aviation, construction, heavy transport and law enforcement. The company believes its voice-based screening technology could provide a faster, more scalable alternative to traditional mouth swab and breathalyzer testing while reducing costs, waste and operational complexity.

To view the full press release, visit https://ibn.fm/Rb8yP

About MindBio Therapeutics Corp.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth

IBN.ai — Thu, 04 Jun 2026 14:20:00 +0000

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining growing investor interest in platform biotech companies as the global drug-delivery market advances toward an estimated $410 billion opportunity. The editorial highlights increasing industry focus on overcoming challenges related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure, while spotlighting Oncotelic’s Sapu003 and Deciparticle platform as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance.

To view the full press release, visit https://ibn.fm/laaQ6

About Oncotelic Therapeutics, Inc.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

IBN.ai — Thu, 04 Jun 2026 14:05:00 +0000

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress.

Fortunately, many companies, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are focused on conducting research and development programs geared at…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a

IBN.ai — Wed, 03 Jun 2026 14:10:36 +0000

TransCode Therapeutics (NASDAQ: RNAZ) announced additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. The company reported durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16 and 21 cycles, supporting advancement of TTX-MC138 into Phase 2a clinical development.

Among 14 evaluable patients, nine (64%) achieved stable disease lasting six months based on RECIST criteria. TransCode also reported pharmacokinetic data demonstrating drug bioavailability consistent with preclinical findings and highlighted a metastatic thyroid cancer patient who experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months. The company said the results support selection of a recommended Phase 2a dose of 4.8 mg/kg and provide a rationale for continued clinical development in patients with limited treatment options.

To view the full press release, visit https://ibn.fm/4WzoX

About TransCode Therapeutics 

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.

NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances Kilogram-Scale Manufacturing for ONC010 Program

IBN.ai — Wed, 03 Jun 2026 13:56:30 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. Conducted through its chemistry, manufacturing and controls collaboration with Dalton Pharma Services, the effort resulted in the production and isolation of approximately 952 grams of B4 material, supporting future formulation development, GMP production and planned clinical studies.

The company said the manufacturing milestone strengthens its integrated development strategy and supports the establishment of a scalable production process for future clinical supply. Onco-Innovations also announced the engagement of InvestorBrandNetwork (“IBN”) to provide market awareness, corporate communications and digital media services through Sept. 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 for the services and intends to apply an unused US$80,000 balance returned from a prior market awareness engagement toward the consideration.

To view the full press release, visit https://ibn.fm/BbWHd

About Onco-Innovations Limited

For more information go to https://oncoinnovations.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

IBN.ai — Wed, 03 Jun 2026 13:50:00 +0000

Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment.
In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records.
Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000.
Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth.
The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June.

For many investors evaluating companies on the OTC market, share structure often receives as much attention as revenue growth or acquisition activity. Earth Science Tech (OTC: ETST), a strategic holding company spanning telemedicine, pharmacies, clinical support services, and healthcare fulfillment, has increasingly distinguished itself in share structure and financial stability through a sustained program of share repurchases, which has reduced outstanding shares while the company simultaneously expands its healthcare-focused operating platform.

The company’s most recent Form 10-Q, covering the quarter ended December 31, 2025, provides a detailed look at the pace of those repurchases (https://ibn.fm/Gm12j). According to the filing, Earth Science Tech repurchased 1,143,000 common shares during the quarter for approximately…

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Expands Patent Portfolio with Ebola Triage Application

IBN.ai — Wed, 03 Jun 2026 13:45:44 +0000

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company’s existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.

Volition said its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. The company is seeking partnerships with global health organizations, pharmaceutical developers, NGOs and distribution partners to support field trials, manufacturing scale-up and potential deployment in outbreak zones.

To view the full press release, visit https://ibn.fm/UOWP1

About Volition

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

For further information, visit the company’s website at https://volition.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies

IBN.ai — Tue, 02 Jun 2026 14:30:47 +0000

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency.

The editorial notes that Oncotelic is advancing its Sapu003 program and Deciparticle(TM) platform as part of a broader trend toward nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy focuses on developing platform technologies with potential applications across multiple oncology and rare disease indications rather than relying on a single therapeutic candidate.

To view the full press release, visit https://ibn.fm/hwkoB

About Oncotelic Therapeutics, Inc.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer

IBN.ai — Tue, 02 Jun 2026 14:15:00 +0000

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data showing that LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data showed a median progression-free survival of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining what the company described as an exceptionally clean safety and tolerability profile, supporting a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles.

To view the full press release, visit https://ibn.fm/uaAUc

ABOUT LANTERN PHARMA INC.

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR(R) platform to transform the development of cancer therapies. Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

IBN.ai — Tue, 02 Jun 2026 14:05:00 +0000

A new viral-based vector that can be inhaled into the lungs could boost the anti-cancer response of the body in patients diagnosed with advanced lung cancer. This new treatment could also restore sensitivity to immune checkpoint inhibitors among patients that had become unresponsive.

These positive results build on the progress that is being made elsewhere by entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are also exploring mechanisms to…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast

IBN.ai — Tue, 02 Jun 2026 13:44:50 +0000

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. Durkacz said the therapy is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.

Durkacz also discussed Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. Looking ahead, he highlighted the company’s upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers.

To view the full press release, visit https://ibn.fm/HURxt

About Quantum BioPharma Ltd.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product

IBN.ai — Tue, 02 Jun 2026 13:22:19 +0000

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product from the production run designated for upcoming clinical research in the United States and clinical trials in Europe.

The company said all stages of manufacturing were completed in-house at its Health Canada-licensed facility, including biomass cultivation, active pharmaceutical ingredient extraction, encapsulation and packaging. Optimi said its vertically integrated platform and commercial-scale production capacity position the company to supply finished psilocybin and MDMA drug products to regulated markets internationally for both patient access programs and clinical research initiatives.

To view the full press release, visit https://ibn.fm/Rx3ky

About Optimi Health Corp.

For more information, please visit www.optimihealth.ca or optimi.net.

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies

IBN.ai — Mon, 01 Jun 2026 14:15:37 +0000

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company’s approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities.

The company is also pursuing a platform-based model through Deciparticle and its AI-enhanced PDAOAI biomedical infrastructure initiative, positioning itself at the intersection of oncology, nanomedicine and artificial intelligence. Growing investor interest in scalable healthcare platforms has coincided with expansion across related sectors, including advanced drug-delivery systems and AI-driven healthcare innovation. Oncotelic joins a group of companies advancing platform-oriented strategies, including Northwest Biotherapeutics (OTCQB: NWBO), Sangamo Therapeutics (OTCQB: SGMO), HIVE Digital Technologies (NASDAQ: HIVE) and Iovance Biotherapeutics (NASDAQ: IOVA).

To view the full press release, visit https://ibn.fm/EU38X

About Oncotelic Therapeutics, Inc.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Shifts Focus to AI Energy Infrastructure, Adds Denham Capital Founder to Board

IBN.ai — Mon, 01 Jun 2026 14:05:00 +0000

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the growing power demands of artificial intelligence and hyperscale data centers. As part of the transition, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company’s board of directors. LIXTE said its strategy will target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies, while it seeks a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.

To view the full press release, visit https://ibn.fm/MVXfg

About LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at www.lixte.com.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https:/ibn.fm/LIXT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference

IBN.ai — Mon, 01 Jun 2026 13:50:37 +0000

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.

To view the full press release, visit https://ibn.fm/1QdP7

About Helus Pharma

NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones

IBN.ai — Fri, 29 May 2026 16:19:23 +0000

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled, positioning Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.

To view a full corporate profile, visit https://ibn.fm/bpPp6

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

US CDC Broadens Ebola Travel Ban to Include Green Card Holders

IBN.ai — Fri, 29 May 2026 14:05:00 +0000

The Centers for Disease Control and Prevention (CDC) in the U.S. has extended the recently issued travel ban on individuals who have been to Uganda, South Sudan, and the Democratic Republic of Congo (DRC) during the past 21 days to now include green card holders. The reason given for this broadened ban is to prevent the disease from being brought into the country by legal permanent residents.

All stakeholders in the healthcare sector, including firms like Astiva Health, are probably getting very concerned about the likelihood of this…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant

IBN.ai — Thu, 28 May 2026 14:47:43 +0000

Regentis Biomaterials Ltd. (NYSE Ame r ican: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.

To view the full article, visit https://ibn.fm/TrCv1

About Regentis Biomaterials

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Climate Change Amplifies Infectious Disease Risks, Experts Warn

IBN.ai — Thu, 28 May 2026 14:05:00 +0000

According to advice published in the Netherlands last week, climate change is increasing the risk of not just infectious diseases but also cancer and heat stress. This concern has implications not just in the U.S. but globally as well.

As the risk of the infectious diseases transmitted by these vectors increases, more will need to be done to increase access to diagnostic services outside centralized labs and into homes and other field conditions so that infected people can be rapidly diagnosed and treated to prevent further spread of any outbreaks. Firms like Co-Diagnostics Inc. (NASDAQ: CODX) are focused on…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026

IBN.ai — Thu, 28 May 2026 13:42:08 +0000

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.

The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform.

To view the full press release, visit https://ibn.fm/RUG7m

About Sapu Nano

Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology.

About Oncotelic Therapeutics, Inc.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Highlights Clinical and Commercial Progress Across Diagnostics Portfolio

IBN.ai — Wed, 27 May 2026 13:40:34 +0000

VolitionRx Limited (NYSE American: VNRX) provided a corporate update highlighting recent clinical and commercial progress, including submission of a feline lymphoma manuscript tied to a potential $5 million milestone payment, alongside continued momentum in licensing discussions with more than a dozen global diagnostic and liquid biopsy companies.

The company also highlighted advancements across its diagnostic pipeline, including validation progress for its Capture-Seq cancer detection platform, expansion of its sepsis-focused Nu.Q NETs program and ongoing efforts to secure reimbursement in France for its lung cancer assay ahead of anticipated routine clinical use.

To view the full press release, visit https://ibn.fm/nX9FK

About Volition

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

For further information, visit the company’s website at https://volition.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences

IBN.ai — Wed, 27 May 2026 13:35:00 +0000

Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.

To view the full press release, visit https://ibn.fm/qFRHu

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Phase 1 TNX-1500 Data Supporting Advancement into Phase 2

IBN.ai — Wed, 27 May 2026 13:27:28 +0000

Tonix Pharmaceuticals (NASDAQ: TNXP) announced publication of peer-reviewed Phase 1 data for TNX-1500, its investigational anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology, highlighting favorable safety, tolerability and pharmacodynamic results in healthy volunteers. The study found TNX-1500 was generally well tolerated with no serious adverse events, demonstrated sustained suppression of T cell-dependent antibody responses and showed a half-life supporting monthly intravenous dosing, supporting advancement toward a planned Phase 2 investigator-initiated kidney transplant rejection study in the second half of 2026, pending FDA clearance.

To view the full press release, visit https://ibn.fm/DHiKX

Tonix Pharmaceuticals Holding Corp.

Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease

IBN.ai — Wed, 27 May 2026 13:15:19 +0000

TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.

To view the full press release, visit https://ibn.fm/wuRri

About TransCode Therapeutics

NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Advances Manufacturing Scale-Up for Lead Oncology Candidate ONC010

IBN.ai — Tue, 26 May 2026 14:42:15 +0000

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) reported continued progress in intermediate-scale manufacturing and process development activities for key precursor components supporting ONC010, the company’s lead nanoparticle-formulated oncology candidate currently advancing through IND-enabling development.

The work, being conducted with Dalton Pharma Services as part of Onco’s integrated chemistry, manufacturing and controls strategy, is focused on process optimization, analytical characterization and manufacturing reproducibility to support future GMP production, regulatory readiness and planned first-in-human clinical development activities in Australia.

To view the full press release, visit https://ibn.fm/Unt8n

About Onco-Innovations Limited

For more information go to https://oncoinnovations.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Aims to Close Critical Gap in Early Cardiac Detection

IBN.ai — Fri, 22 May 2026 19:34:53 +0000

HeartBeam (NASDAQ: BEAT) is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising clinical need and evolving innovation. “One of the most persistent challenges in cardiac care is pre-hospital delay, with many patients not seeking medical attention at the onset of symptoms. Traditional electrocardiogram testing is typically conducted in clinical environments, which may not coincide with the onset of symptoms such as intermittent chest pain, palpitations or other warning signs. As a result, patients often defer care and clinicians are left without the data needed to make timely, informed decisions,” reads a recent article.

“HeartBeam is working to address this gap by transforming how ECG data are collected and used. The company’s HeartBeam System is designed as a cable-free, high-fidelity ECG platform capable of capturing the heart’s electrical signals from three distinct directions for arrhythmia assessment. By collecting multidirectional signals, the system is intended to provide a more comprehensive representation of cardiac activity compared with conventional single-lead devices… The HeartBeam System uses a compact, credit-card size, portable design with embedded electrodes that allow patients to record ECG signals without adhesive patches or wires. This simplifies the user experience while maintaining the quality of data needed for clinical interpretation. The system’s ability to generate synthesized 12-lead ECG signals from these recordings is particularly significant, as it brings a level clinical-grade data traditionally associated with hospital-based equipment into a portable format. The HeartBeam System is currently FDA cleared for arrhythmia assessment and the company plans to submit for an indication expansion for heart attack detection in the future.”

To view the full article, visit https://ibn.fm/X6IEc

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Study Finds That Errors in Brain Cell Division Could Trigger Cancer

IBN.ai — Fri, 22 May 2026 14:05:00 +0000

Researchers at the University of Virginia have conducted a study that offers new insights into what happens when there are errors in the process of brain cells dividing to form new cells as the brain is growing. Their findings could open the door to treating cancer and many developmental disorders of the brain.

It may also be possible to prevent many birth defects once the process through which defective cells are removed is better understood. It would be interesting to hear what firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) have to say about the…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

IBN.ai — Thu, 21 May 2026 16:56:08 +0000

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising.

SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments,” a recent article reads. “Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic. Through its acquisition of GlucaPharm Inc., the company holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University, and is progressing the asset through the U.S. Food and Drug Administration (‘FDA’) pathway with the goal of advancing it into clinical development.”

To view the full article, visit https://ibn.fm/cTKmO

About SureNano Science Ltd.
SureNano Science is focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. The initial business of SureNano Science is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.

NOTE TO INVESTORS: The latest news and updates relating to SURNFare available in the company’s newsroom at https://ibn.fm/SURNF

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Scientists Inch Closer to Developing a Lung Cancer Blood Test

IBN.ai — Thu, 21 May 2026 14:05:00 +0000

Unlike prostate, colon and breast cancers, the screening for lung cancer hasn’t been very successful. This is largely because screening focuses on just one risk factor, smoking history, yet many people who develop the disease don’t have a history of smoking. Now, scientists have made progress in developing a blood test that could help in flagging individuals who are at a higher risk of developing lung cancer.

As it gets easier to detect lung cancer earlier, new treatment modalities like those being developed by Calidi Biotherapeutics Inc. (NYSE American: CLDI) and therapies under development by…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Launches MyndSystem Cognitive Support Platform

IBN.ai — Thu, 21 May 2026 13:52:04 +0000

BioAdaptives (OTC: BDPT) a science-driven health and wellness company, announced the launch of MyndSystem, a dual-phase cognitive support platform combining its daytime MyndMed formula with newly released nighttime recovery product MyndRenew into a 24-hour stimulant-free cognitive support system. The company said MyndSystem was originally developed for professional combat athletes and is designed to address both daytime mental performance and overnight neural recovery.

MyndMed is a 12-ingredient daytime formula intended to support focus, mental clarity and cognitive endurance, while MyndRenew is a 14-ingredient nighttime formula designed to support the brain’s overnight repair processes, according to the company. BioAdaptives said the complete MyndSystem platform is now available for purchase as a 30-day supply through direct purchase or subscription.

To view the full press release, visit https://ibn.fm/ZyE8c

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for human and animal use. Its formulations are rooted in published research across nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

For more information, please visit our website at www.bioadaptives.com.

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering

IBN.ai — Wed, 20 May 2026 15:45:06 +0000

Sunshine Biopharma (NASDAQ: SBFM) announced the closing of its previously announced public offering, generating approximately $6 million in gross proceeds before fees and expenses through the sale of 12 million common units, each including common stock or pre-funded warrants and two Series C warrants. The company said net proceeds will be used for general corporate purposes and working capital, with potential additional gross proceeds of approximately $12 million if the Series C warrants are fully exercised for cash, while Aegis Capital acted as exclusive placement agent.

To view the full press release, visit https://ibn.fm/XuHPC

About Sunshine Biopharma Inc.

Sunshine Biopharma currently markets 60 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:

K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.

PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.

Additional information is available at https://sunshinebiopharma.com/

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) CEO Highlights Growth Strategy, India Expansion on BioMedWire Podcast

IBN.ai — Wed, 20 May 2026 13:50:48 +0000

Cardio Diagnostics Holdings (NASDAQ: CDIO), took the spotlight in the latest episode of The BioMedWire Podcast, featuring CEO and Co-Founder Dr. Meesha Dogan discussing the company’s mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics and artificial intelligence. During the interview, Dogan also highlighted Cardio Diagnostics’ expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs, as well as the company’s progress through the Medicare reimbursement process, noting that CPT coding and payment steps have been completed while coverage determination remains underway.

To view the full press release, visit https://ibn.fm/0VjIz

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Eilon Elmalem as Head of Yavne CDMO Facility

IBN.ai — Wed, 20 May 2026 13:31:38 +0000

Scinai Immunotherapeutics (NASDAQ: SCNI) announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience and will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform.

To view the full press release, visit https://ibn.fm/VLt3w

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants

IBN.ai — Wed, 20 May 2026 13:05:00 +0000

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced a proposed underwritten public offering of common stock and accompanying warrants. The company intends to use net proceeds to support continued clinical development of buntanetap in a Phase 3 Alzheimer’s disease study, as well as for working capital and general corporate purposes.

To view the full press release, visit https://ibn.fm/1cxGA

About Annovis

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech with AI-Enhanced Robotics Strategy

IBN.ai — Tue, 19 May 2026 18:02:52 +0000

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. “Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments,” reads a recent article. “At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings.”

To view the full article, visit https://ibn.fm/FnE7R

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Health Care Affordability Crisis Creates Momentum for Single-Payer System in Massachusetts

IBN.ai — Tue, 19 May 2026 14:05:00 +0000

As the cost of health care skyrockets across the U.S., residents in many states are mobilizing to push their state governments to enact laws creating a single-payer system as a way of making health care more affordable for everyone. This movement is especially gaining traction in Massachusetts.

As these grassroots movements gain traction and cause change to state laws, the impact could be felt at the federal level, and possibly trigger meaningful change at the national level. This trend is something that entities like Astiva Health that offer health coverage in other states will be watching because it…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Phase IIa Progress and Strategic CNS Expansion Plans

IBN.ai — Mon, 18 May 2026 13:55:00 +0000

Oragenics (NYSE American: OGEN) provided a shareholder update outlining progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury in Australia, with active patient enrollment and dosing underway across multiple sites, while advancing U.S. regulatory preparations targeting a Type C FDA meeting request in the second quarter and IND submission by year-end 2026. The company also disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device and reported a March 31, 2026, cash balance of $6.1 million.

To view the full press release, visit https://ibn.fm/tEk2C

About Oragenics, Inc.

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study

IBN.ai — Mon, 18 May 2026 13:25:00 +0000

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026.

To view the full press release, visit https://ibn.fm/4IZ0y

About Quantum BioPharma Ltd.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Wastewater Monitoring Could Help in Early Prediction of Influenza Outbreaks

IBN.ai — Fri, 15 May 2026 14:05:00 +0000

Seasonal influenza often spreads rapidly, and timely data can help policymakers and the health care system make the right decisions on matters like resource planning. A new study conducted in Japan suggests that monitoring wastewater could be a helpful way of learning in advance how influenza outbreaks are likely to manifest a week before data on patients affected flag outbreak trends.

This modeling approach is especially useful in areas where advanced diagnostic facilities aren’t readily accessible and communities aren’t adequately active in seeking medical care. As companies like Co-Diagnostics Inc. (NASDAQ: CODX) work tirelessly to bring to market more reliable diagnostic tools that…

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Development Across Multiple Viral Disease Targets

IBN.ai — Fri, 15 May 2026 13:58:18 +0000

NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, highlighting continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox.

To view the full press release, visit https://ibn.fm/osO0q

About NanoViricides

NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Subsidiary Active Intelligence to Showcase Wellness Products at ECRM Conference

IBN.ai — Fri, 15 May 2026 13:36:50 +0000

Nutriband (NASDAQ: NTRB) announced that its wholly owned subsidiary, Active Intelligence, will participate in the June 2026 ECRM conference, where it plans to showcase its expanding portfolio of wellness, recovery and performance-focused consumer products to buyers from major retail, pharmacy and healthcare organizations. The company will feature its existing AI Tape line and introduce new products including AI Performance Tape, AI Energy Patches and AI Sleep as it seeks to expand retail partnerships and distribution opportunities.

To view the full press release, visit https://ibn.fm/sZ1zJ

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com . Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About BioMedWire

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com